Fig. 3

Characterization of the TMZ-treated C6TMZ, C6R2TMZ and the in vivo control C6R1 cell lines. a Brain magnetic resonance imaging (MRI) of the vehicle and TMZ-treated C6R1 and C6R2TMZ gliomas after 2 weeks of treatment. b Representative karyograms of C6 and C6TMZ. The structurally abnormal chromosomes are marked. c Distribution of chromosomes across 200 metaphases for each designated cell line. d The karyotype differences between cell lines were demonstrated by alignment and comparison of karyographs of vehicle- and TMZ-treated derivatives. A list of all CCAs/NCCAs (in the same order as depicted on the x-axis of karyographs) and their copy number variation can be found in Additional file 5: Table S5. e A summary of karyotypic parameters of each cell line. f The chromosome ideograms show the areas of genetic gain/loss. Detailed description of copy number alterations (CNAs) can be found in Additional file 6: Table S6